Regarding the k9 subtype, specific to renal cell carcinoma in the CPTAC cohort, increased hemoglobin has been associated elsewhere with VEGF inhibitor treatment in advanced renal cell carcinoma26, and elevation in hemoglobin on VEGF-directed therapy has been associated with worse clinical outcomes27. Here, VEGFA is linked to hereditary clear cell renal cell carcinoma.